The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group
To access this article, please choose from the options below
PII: S0145-2126(10)00247-X
doi:10.1016/j.leukres.2010.05.003
© 2010 Elsevier Ltd. All rights reserved.
